READ: Prime/MRx releases year-2 GLP-1 data

Prime Therapeutics/Magellan Rx Management (Prime/MRx) is excited to share findings from our second year of research into glucagon-like peptide-1 (GLP-1) receptor agonist weight loss therapy. The press release, which was released on July 10, features findings of Prime/MRx’s continued research into real-world use of GLP-1 drugs for weight loss and will present adherence/persistence data for individuals who have continued therapy for a second year. This is a continuation of Prime/MRx’s industry leading data on first-year GLP-1 weight loss therapy, which was announced in July 2023.

Press release highlights

• 85% of individuals who started GLP-1 drugs for weight loss were no longer taking the drug after two years — a further 14% point decrease in persistence in just one year.
• At two years, 26% of individuals switched GLP-1 drugs during therapy — an increase from 11% at one year.

Want to learn more about Prime/MRx’s holistic GLP-1 strategy?
​​​​​We take an evidence-based approach for GLP-1 drugs, working with our partners to develop individualized strategies that promote clinically appropriate use and member health outcomes. See our strategy, analysis and more on our GLP-1 Strategy page.